ASX - Delayed Quote AUD

BCAL Diagnostics Limited (BDX.AX)

0.0820
+0.0020
+(2.50%)
At close: May 16 at 4:10:21 PM GMT+10
Loading Chart for BDX.AX
  • Previous Close 0.0800
  • Open 0.0810
  • Bid 0.0800 x --
  • Ask 0.0820 x --
  • Day's Range 0.0770 - 0.0820
  • 52 Week Range 0.0720 - 0.1850
  • Volume 300,412
  • Avg. Volume 268,838
  • Market Cap (intraday) 30.009M
  • Beta (5Y Monthly) 0.65
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0300
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 0.20

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a novel blood screening test to improve the diagnosis and monitoring of breast cancer. It develops BREASTEST, a laboratory developed test or in-house in vitro diagnostic blood test. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

www.bcaldiagnostics.com

--

Full Time Employees

June 30

Fiscal Year Ends

Recent News: BDX.AX

View More

Performance Overview: BDX.AX

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

BDX.AX
15.46%
S&P/ASX 200 [XJO] (^AXJO)
2.26%

1-Year Return

BDX.AX
25.45%
S&P/ASX 200 [XJO] (^AXJO)
5.87%

3-Year Return

BDX.AX
8.89%
S&P/ASX 200 [XJO] (^AXJO)
17.63%

5-Year Return

BDX.AX
67.84%
S&P/ASX 200 [XJO] (^AXJO)
54.38%

Compare To: BDX.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BDX.AX

View More

Valuation Measures

As of 5/16/2025
  • Market Cap

    30.01M

  • Enterprise Value

    24.30M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.24

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -48.05%

  • Return on Equity (ttm)

    -104.23%

  • Revenue (ttm)

    2.62M

  • Net Income Avi to Common (ttm)

    -7.99M

  • Diluted EPS (ttm)

    -0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.01M

  • Total Debt/Equity (mrq)

    14.07%

  • Levered Free Cash Flow (ttm)

    -4.79M

Research Analysis: BDX.AX

View More

People Also Watch